Skip to main content

MiMedx Group, Inc. (MDXG)

NASDAQ: MDXG · IEX Real-Time Price · USD
6.25 -0.01 (-0.16%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap699.69M
Revenue (ttm)260.98M
Net Income (ttm)-83.17M
Shares Out111.95M
EPS (ttm)-0.77
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume989,905
Open6.20
Previous Close6.26
Day's Range6.13 - 6.44
52-Week Range5.30 - 15.99
Beta1.65
Analystsn/a
Price Target13.83 (+121.3%)
Est. Earnings DateNov 3, 2021

About MDXG

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers,...

IndustryBiotechnology
Employees735
Stock ExchangeNASDAQ
Ticker SymbolMDXG
Full Company Profile

Financial Performance

In 2020, MiMedx Group's revenue was $248.23 million, a decrease of -17.05% compared to the previous year's $299.26 million. Losses were -$83.33 million, 225.8% more than in 2019.

Financial Statements

News

Why Shares of MiMedx Are Collapsing Today

The company released data for two drug programs and missed its goals on both.

1 week ago - The Motley Fool

Why MiMedx Shares Are Diving Today

MiMedx Group Inc (NASDAQ: MDXG) is trading significantly lower Monday after the company announced top-line results from two late-stage musculoskeletal clinical trials.  Top-line results from an interim ...

1 week ago - Benzinga

Mimedx Stock Plunges After Disappointing Data From Musculoskeletal Trials

MiMedx Group Inc (NASDAQ: MDXG) stock dropped after announcing top-line results from two musculoskeletal trials of micronized dehydrated Human Amnion Chorion Membrane (mdHACM). Top-line results from an ...

1 week ago - Benzinga

MIMEDX Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue Technology

Phase 2B Knee Osteoarthritis (KOA) Study Top-line Interim Results Demonstrate Varied Efficacy Signals between Patient Cohorts

2 weeks ago - GlobeNewsWire

MIMEDX Announces Effectiveness of Shelf Registration Statement

MARIETTA, Ga., Sept. 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, ...

2 weeks ago - GlobeNewsWire

MIMEDX to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

MARIETTA, Ga., Sept. 07, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, ...

2 weeks ago - GlobeNewsWire

MIMEDX Announces Filing of Shelf Registration Statement with Securities and Exchange Commission

S-3 Eligibility Enabled by Accomplishment of Multiple Financial Milestones

4 weeks ago - GlobeNewsWire

Medicare Data: Significant Reductions in Amputations, Emergency Visits, and Hospital Readmissions Associated with Adv...

New study shows advanced treatment (AT) for management of LEDUs among Medicare beneficiaries is associated with significant reductions in major and minor amputation, emergency department (ED) use, and h...

1 month ago - GlobeNewsWire

MIMEDX Promotes Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs

Promotion Recognizes Skilled Leadership and Contributions to MIMEDX's Continued Growth

1 month ago - GlobeNewsWire

MIMEDX Announces Second Quarter 2021 Operating and Financial Results

Second Quarter Net Sales Increase 27% to $68.2 million Versus Q2 2020

1 month ago - GlobeNewsWire

NAACP to Present Historic Spingarn Medal to Regenerative Engineering Pioneer Cato T. Laurencin, M.D.

MIMEDX Applauds Dr. Laurencin on Receiving NAACP's Highest Honor for His Contributions to Emerging Medical Sciences that Advance Human Healing

2 months ago - GlobeNewsWire

MIMEDX Joins Russell 3000® and 2000® Indexes

MARIETTA, Ga., June 28, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, t...

2 months ago - GlobeNewsWire

MIMEDX to Present at the Raymond James 2021 Human Health Innovation Conference

MARIETTA, Ga, June 16, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, to...

3 months ago - GlobeNewsWire

New Study Demonstrates Potential for MIMEDX Purion® Processed Dehydrated Human Amnion/Chorion Membrane to Modulate Pa...

Proposed Mechanism Suggests Potential Path to Improve Outcomes in Clinical Applications where the Regulation of Excessive Fibrosis Can Promote a Normal Healing Response

3 months ago - GlobeNewsWire

Former Penny Stocks That Exploded in Value, One Up Over 3,500%

These former penny stocks hit it big since 2020; are they on your watchlist? The post Former Penny Stocks That Exploded in Value, One Up Over 3,500% appeared first on Penny Stocks to Buy, Picks, News an...

Other symbols:MVISNVAXPLUG
3 months ago - PennyStocks

MIMEDX to Participate at the Jefferies Virtual Healthcare Conference

MARIETTA, Ga., May 27, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, to...

3 months ago - GlobeNewsWire

MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2021 Annual Meeting of Shareholders

Deadline to Pre-Register Extended to May 26, 2021 at 10:00 a.m. Eastern

4 months ago - GlobeNewsWire

MIMEDX Reminds Shareholders to Vote at the Upcoming Annual Meeting

Vote FOR MIMEDX's Experienced and Highly Qualified Directors and Governance Enhancement Proposals

4 months ago - GlobeNewsWire

MIMEDX to Participate at Upcoming Investor Conferences

MARIETTA, Ga., May 10, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, to...

4 months ago - GlobeNewsWire

Prescience Point Announces Withdrawal of Its Slate of Nominees to MiMedx's Board

BATON ROUGE, La., May 4, 2021 /PRNewswire/ -- Prescience Point Capital Management ("Prescience Point"), a research-focused, catalyst-driven investment firm that is the beneficial owner of approximately ...

4 months ago - PRNewsWire

MIMEDX Urges Shareholders to Consider Prescience Point's Motivations Before Voting Their Shares at the Company's Annu...

Questions Every Shareholder Should Ask Prescience Point

4 months ago - GlobeNewsWire

MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIME...

Urges Shareholders to Vote the WHITE Proxy Card “FOR ALL” Four of MIMEDX's Director Nominees – Dr. Kathleen Behrens, Mr. Todd Newton, Mr. Timothy Wright, and Dr. Phyllis Gardner

4 months ago - GlobeNewsWire

MiMedx Announces First Quarter 2021 Financial and Operating Results

First Quarter Net Sales of $60.0 Million

4 months ago - GlobeNewsWire

MiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs

Accomplished Regulatory Leader Joins MiMedx Management Team

4 months ago - GlobeNewsWire

MiMedx to Host First Quarter 2021 Operating and Financial Results Conference Call on April 29

MARIETTA, Ga., April 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, ...

5 months ago - GlobeNewsWire